BDTX Insider Shannon Campbell Buys 40,000 Shares

Shannon Campbell, an insider at Black Diamond Therapeutics, Inc. (NasdaqGS: BDTX), purchased 40,000 shares on June 26, 2026. This insider transaction did not specify a purchase price, but it reflects a notable acquisition of shares in the company.

Insider Buying and Selling at Black Diamond Therapeutics, Inc.

Several insiders, including Shannon Campbell, Garry Menzel, and Prakash Raman, each acquired 40,000 shares of Black Diamond Therapeutics on June 26, 2026. These transactions were not part of any prearranged trading plans, suggesting a direct investment decision by these insiders.

Black Diamond Therapeutics, Inc. Stock Down 10.7%

Shares of Black Diamond Therapeutics traded near $1.75 on Tuesday. The company, which operates in the biotechnology sector, has a market cap of approximately $98 million. Black Diamond Therapeutics is not currently profitable, resulting in no meaningful P/E ratio. The stock has a beta of 3.233, indicating significant volatility. Its 52-week range is between $1.60 and $4.94, with a 50-day moving average of $2.45 and a 200-day moving average of $2.85.

Analysts Set New Price Targets

Recent analyst activity shows continued confidence in Black Diamond Therapeutics. On April 29, 2026, BTIG maintained its buy rating with an $11 price target. Other firms, including Wedbush and Piper Sandler, have also reiterated buy ratings with targets as high as $14. The consensus target price for the stock is around $9.86, based on seven analyst opinions.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company based in Cambridge, Massachusetts. It focuses on developing therapies for genetically defined tumors. The company's lead product candidate, silevertinib, is in Phase 2 trials for treating specific types of cancer. Black Diamond also has other pipeline candidates targeting various oncogenic mutations. Dr. Mark A. Velleca serves as the CEO, leading a team of 21 employees.

Bottom Line

The recent insider buying activity at Black Diamond Therapeutics is noteworthy as it reflects potential confidence in the company's future prospects. While the stock is volatile, analysts have maintained positive ratings, suggesting a favorable outlook. As always, it's important to remember that insider transactions are disclosed after they occur and may not indicate immediate changes in stock performance.